Olema Pharmaceuticals
OLMA
126 hedge funds and large institutions have $635M invested in Olema Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
27% more call options, than puts
Call options by funds: $664K | Put options by funds: $521K
12% more funds holding
Funds holding: 113 → 126 (+13)
5.19% more ownership
Funds ownership: 95.15% → 100.34% (+5.2%)
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
12% less capital invested
Capital invested by funds: $724M → $635M (-$88.9M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$32.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$16.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.5M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$9.09M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$8.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$34.5M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$8.85M |
| 3 |
PA
Perceptive Advisors
New York
|
-$7.57M |
| 4 |
Morgan Stanley
New York
|
-$6.42M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$4.21M |
OLMA Hedge Fund Activity: Q1 2024 in Review
126 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2024, worth a combined $635M — down 12% from $724M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new OLMA positions and 17 closed out — a net gain of 13 holders — while 39 added to existing stakes and 36 trimmed.
The largest buyer was State Street, adding an estimated $32.3M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $34.5M sold.
- 126 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2024, up from 113 in Q4 2023.
- Funds reported $635M of Olema Pharmaceuticals stock for Q1 2024, down 12% quarter-over-quarter.
- 30 funds opened new Olema Pharmaceuticals positions in Q1 2024 and 17 closed out, a net change of +13 holders.
- The largest Olema Pharmaceuticals buyer in Q1 2024 was State Street, an estimated $32.3M added.
- The largest Olema Pharmaceuticals seller in Q1 2024 was Cormorant Asset Management, an estimated $34.5M sold.
Based on aggregated 13F filings for Q1 2024.